SECOND LINE TREATMENT PERSISTENCE AND COSTS AMONG PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASES TREATED WITH SUBCUTANEOUS TNF-ALPHA INHIBITORS

被引：0
|
作者：
Dalen, J. [1 ]
Svedbom, A. [1 ]
Black, C. M. [2 ]
Kachroo, S. [2 ]
机构：
[1] Mapi Grp, Stockholm, Sweden
[2] Merck & Co Inc, Kenilworth, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.2654
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0640
引用
收藏
页码：447 / 447
页数：1
相关论文
共 50 条
  • [1] Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors
    Dalen, Johan
    Svedbom, Axel
    Black, Christopher M.
    Kachroo, Sumesh
    [J]. RHEUMATOLOGY INTERNATIONAL, 2017, 37 (12) : 2049 - 2058
  • [2] Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors
    Johan Dalén
    Axel Svedbom
    Christopher M. Black
    Sumesh Kachroo
    [J]. Rheumatology International, 2017, 37 : 2049 - 2058
  • [3] Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
    Svedbom, Axel
    Dalen, Johan
    Black, Christopher M.
    Kachroo, Sumesh
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 95 - 106
  • [4] FIRST AND SECOND LINE TREATMENT PERSISTENCE AMONG PATIENTS WITH IMMUNE-MEDIATED RHEUMATOID DISEASE TREATED WITH SUBCUTANEOUS TNF-ALPHA INHIBITORS
    Dalen, J.
    Svedbom, A.
    Black, C. M.
    Kachroo, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 877 - 877
  • [5] Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
    Johan Dalén
    Axel Svedbom
    Christopher M. Black
    Ramon Lyu
    Qian Ding
    Shiva Sajjan
    Vasilisa Sazonov
    Sumesh Kachroo
    [J]. Rheumatology International, 2016, 36 : 987 - 995
  • [6] Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
    Dalen, Johan
    Svedbom, Axel
    Black, Christopher M.
    Lyu, Ramon
    Ding, Qian
    Sajjan, Shiva
    Sazonov, Vasilisa
    Kachroo, Sumesh
    [J]. RHEUMATOLOGY INTERNATIONAL, 2016, 36 (07) : 987 - 995
  • [7] TREATMENT PERSISTENCE OF SUBCUTANEOUS TNF-ALPHA INHIBITORS AMONG AUSTRALIAN PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASE (IMRD)
    Acar, M.
    Juneja, P.
    Agnew, J.
    Handel, M.
    [J]. INTERNAL MEDICINE JOURNAL, 2017, 47 : 24 - 24
  • [8] Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)
    Acar, Mustafa
    Juneja, Prabhjot
    Handel, Malcolm
    [J]. OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2018, 10 : 151 - 160
  • [9] Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study
    Carballo, Nuria
    Garcia-Alzorriz, Enric
    Ferrandez, Olivia
    Navarrete-Rouco, Maria Eugenia
    Duran-Jorda, Xavier
    Perez-Garcia, Carolina
    Monfort, Jordi
    Cots, Francesc
    Grau, Santiago
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [10] Impact of Non-Persistence on Healthcare Resource Utilization Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study (vol 12, 752879, 2021)
    Carballo, Nuria
    Garcia-Alzorriz, Enric
    Ferrandez, Olivia
    Navarrete-Rouco, Maria Eugenia
    Duran-Jorda, Xavier
    Perez-Garcia, Carolina
    Monfort, Jordi
    Cots, Francesc
    Grau, Santiago
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
12345